Table 4

Rates of routinely recommended laboratory tests for pregnant womena, and rates of CMV-specific testing among pregnant womena with claims for routinely recommended laboratory tests, MarketScan, 2009
Routinely recommended laboratory tests for pregnant womena Pregnant womena Pregnant womena with CMV-specific testingb
# (%) # (%)
Anemia testing 10,033 (13) 146 (1.5)
Glucose testing 54,989 (71) 1,228 (2.2)
Urine testing 54,947 (71) 1,311 (2.4)
Syphilis testing 65,047 (84) 1,613 (2.5)
Chlamydia testing 49,730 (64) 1,225 (2.5)
HIV testing 57,262 (74) 1,530 (2.7)
Hepatitis B testing 23,011 (30) 800 (3.5)
Rubella testing 15,546 (20) 650 (4.2)

Note: CMV, cytomegalovirus; PCR, polymerase chain reaction; IgG, Immunoglobulin G; IgM, Immunoglobulin M; DFA, direct fluorescent testing; EIA, enzyme immunoassay.

aPregnant women defined as female enrollees who were 1) aged 15–44 years, 2) enrolled for the entire year in 2009, and 3) had a delivery code (defined in Appendix) between October-December 2009.

bCMV-specific testing includes CMV IgG, CMV IgM, CMV DFA, CMV EIA, and CMV PCR testing.

Leung et al.

Leung et al. BMC Infectious Diseases 2012 12:334   doi:10.1186/1471-2334-12-334

Open Data